JXN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Jackson Financial Inc. (JXN) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available. Despite positive hedge fund activity and some bullish technical indicators, the company's weak financial performance in the latest quarter, lack of recent news catalysts, and mixed analyst sentiment suggest a cautious approach. The stock may be worth monitoring, but it does not currently present a compelling entry point.
The technical indicators present a mixed picture. The MACD is negative and expanding downward, suggesting bearish momentum. RSI is neutral at 29.737, indicating no clear signal. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near a key support level at S1: 111.436. The pivot point is at 116.887, indicating potential resistance above the current price.
Hedge funds have significantly increased their buying activity, up 1444.89% over the last quarter. Analysts have recently raised price targets, with Barclays increasing its target to $137 and maintaining an Overweight rating, citing strong capital strength and cash flow.
The company's financial performance in Q3 2025 was weak, with revenue down -34.58% YoY, net income down -113.54% YoY, and EPS down -114.44% YoY. Additionally, there is no recent news or congress trading data to provide positive momentum. The options market sentiment is bearish, with a high put-call volume ratio.
In Q3 2025, Jackson Financial reported a significant decline in financial metrics. Revenue dropped to $1.396 billion (-34.58% YoY), net income fell to $65 million (-113.54% YoY), and EPS decreased to 0.92 (-114.44% YoY). Gross margin remained flat at 0%. These results indicate a challenging financial environment for the company.
Analyst sentiment is mixed. Barclays raised its price target to $137 and maintains an Overweight rating, citing strong fundamentals. Evercore ISI upgraded the stock to In Line from Underperform with a price target of $118, highlighting manageable risks. However, Morgan Stanley remains cautious with an Equal Weight rating and a price target of $105, citing industry challenges and macroeconomic headwinds.
